within Pharmacolibrary.Drugs.ATC.B;

model B02AA02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.0018333333333333333,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005666666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B02AA02_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, thereby preventing fibrinolysis and stabilizing blood clots. It is primarily used to treat or prevent excessive bleeding in various medical conditions, including during surgery, trauma, heavy menstrual bleeding (menorrhagia), and in certain bleeding disorders. Tranexamic acid is approved for use in many countries worldwide.</p><h4>Pharmacokinetics</h4><p>Oral administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Grassin-Delyle, S, Semeraro, M, Lamy, E, Urien, S, Runge, I, Foissac, F, Bouazza, N, Treluyer, JM, Arribas, M, Roberts, I, &amp; Shakur-Still, H (2022). Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. <i>British journal of anaesthesia</i> 128(3) 465–472. DOI:<a href=\"https://doi.org/10.1016/j.bja.2021.10.054\">10.1016/j.bja.2021.10.054</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34998508/\">https://pubmed.ncbi.nlm.nih.gov/34998508</a></p></li><li><p>Cortegiani, A, Absalom, AR, &amp; Hunt, BJ (2021). Intramuscular tranexamic acid: a real-world application of pharmacokinetics. <i>British journal of anaesthesia</i> 126(1) 17–20. DOI:<a href=\"https://doi.org/10.1016/j.bja.2020.10.003\">10.1016/j.bja.2020.10.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33131654/\">https://pubmed.ncbi.nlm.nih.gov/33131654</a></p></li><li><p>Kane, Z, Picetti, R, Wilby, A, Standing, JF, Grassin-Delyle, S, Roberts, I, &amp; Shakur-Still, H (2021). Physiologically based modelling of tranexamic acid pharmacokinetics following intravenous, intramuscular, sub-cutaneous and oral administration in healthy volunteers. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 164 105893–None. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2021.105893\">10.1016/j.ejps.2021.105893</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34087356/\">https://pubmed.ncbi.nlm.nih.gov/34087356</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B02AA02_1;
